Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) CEO Saurabh Saha Sells 55,000 Shares of Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction on Monday, July 21st. The shares were sold at an average price of $15.92, for a total value of $875,600.00. Following the sale, the chief executive officer owned 221,017 shares of the company’s stock, valued at approximately $3,518,590.64. The trade was a 19.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Friday, June 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $12.63, for a total value of $694,650.00.
• On Tuesday, May 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $12.71, for a total value of $699,050.00.

Centessa Pharmaceuticals Stock Up 2.4%

Shares of NASDAQ CNTA opened at $16.06 on Tuesday. The company has a current ratio of 14.37, a quick ratio of 14.37 and a debt-to-equity ratio of 0.28. The company has a market cap of $2.14 billion, a price-to-earnings ratio of -8.87 and a beta of 1.45. Centessa Pharmaceuticals PLC Sponsored ADR has a 12 month low of $9.00 and a 12 month high of $19.09. The stock has a 50-day moving average price of $13.24 and a two-hundred day moving average price of $14.42.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.15. As a group, analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds have recently bought and sold shares of CNTA. GF Fund Management CO. LTD. purchased a new stake in shares of Centessa Pharmaceuticals in the 4th quarter worth $31,000. Caitong International Asset Management Co. Ltd boosted its position in Centessa Pharmaceuticals by 15,209.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock worth $46,000 after purchasing an additional 3,194 shares in the last quarter. Osterweis Capital Management Inc. purchased a new position in shares of Centessa Pharmaceuticals in the first quarter valued at approximately $47,000. Barclays PLC increased its holdings in shares of Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after purchasing an additional 4,952 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Centessa Pharmaceuticals during the first quarter worth $147,000. Institutional investors own 82.01% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CNTA. Guggenheim restated a “buy” rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Wall Street Zen upgraded Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Needham & Company LLC started coverage on Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They set a “buy” rating and a $35.00 target price on the stock. Oppenheimer began coverage on Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued an “outperform” rating and a $6.00 price target for the company. Finally, Chardan Capital assumed coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued a “buy” rating and a $30.00 price target for the company. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $28.10.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.